Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  La Mantia, Loredana ^a,b   Di Pietrantonj, Carlo ^c   Rovaris, Marco ^a   Rigon, Giulio ^d   Frau, Serena ^e   Berardo, Francesco ^f   Gandini, Anna ^g   Longobardi, Anna ^d   Weinstock Guttman, Bianca ^h   Vaona, Alberto ^d  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c SeREMI   (Italy)

^d Divisione Lungodegenza Medica   (Italy)

^e Dialogo sui Farmaci Srl   (Italy)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

^g Regional Health Service   (Italy)

^h UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO; STEROID; IMMUNOLOGICAL ADJUVANT; PEPTIDE;

BRAIN ATROPHY; BRAIN SIZE; COMBINATION DRUG THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; META ANALYSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84922394881     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009333.pub2     Document Type: Review

References (112)

1. Cadavid D, Cheriyan J, SkurnickJ, LincolnJ A, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal Neurology Neurosurgery and Psychiatry 2009;80:1337-43.
2. Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Multiple Sclerosis Journal 2011;17(9):1113-21.
3. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72(23):1976-83.
4. Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Archives of Neurology 2012;69:82-8.
5. NCT00176592. Phase IV, rater-blinded, randomized study comparing 250 mg of Betaseron with 20 mg of Copaxone in patients with the relapsing-remitting (RR) or CIS forms of ms using 3 Tesla (3T) magnetic resonance imaging (MRI) with triple-dose gadolinium. http://clinicaltrials.gov/ct2/show/NCT00176592 (accessed 25 October 2013).
6. Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, Rinaldi F, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 2012;18(4):418-24.
7. Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Multiple Sclerosis and Related Disorders 2012;1:81-6.
8. Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis -clinical outcomes. Proceedings of Neurology vol 78, abstracts 1, PL02.003, April 27. 2012. [64th American Academy of Neurology Annual Meeting, New Orleans]
9. Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Proceedings of Neurology vol 80, P04.121, abstract 1, February 12. 2013. [The American Academy of Neurology's 65th AAN Annual Meeting, San Diego]
10. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology 2013;73:327-40.
11. Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis -MRI outcomes. Proceedings of Neurology vol 78, abstracts S11.002, April 24. 2012. [64th American Academy of Neurology Annual Meeting, New Orleans]
12. Wolinsky J, Salter A, Narayana P, Datta S, Nelson F, Cofield S, et al. MRI outcomes in CombiRx: blinded, 7-year extension results. Proceedings of Neurology vol 80, abstract 1, S01.003, February 12. 2013. [The American Academy of Neurology's 65th AAN Annual Meeting, San Diego]
13. Coyle PK, Cornelisse P, Lehr L, Stubinski B. Time course of injection-site reactions to subcutaneous interferon beta-1a or glatiramer acetate in the REGARD Study. Proceedings of the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 2-5, San Antonio, Texas, USA. 2010.
14. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology 2008;7(10):903-14.
15. Sørensen S. REGARD: what can we learn from randomised, open-label, head-to-head studies?. The Lancet 2008;7:864-6.
16. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, et al. Interferon-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76:1222-8.
17. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the beyond trial. Multiple Sclerosis 2012;18:181-95.
18. Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, et al. Efficacy and safety of interferon beta-1b SC in older RRMS patients-a post hoc analysis of the BEYOND study. Journal of Neurology 2013;260(7):1838-45.
19. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurology 2009;8(10):889-97.
20. O'Connor P, Arnason B, Comi GC, Filippi M, Cook S, Newark NJ, et al. Interferon beta-1b 500 mcg, Interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the betaferon® efficacy yielding outcomes of a new dose study. Proceeding of the 60th American Academy of Neurology Annual Meeting 153 vol 71 LBS.004. 2008.
21. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2011; Vol. 10, issue 2:115.
22. O'Connor P, Filippi M, Arnason B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2009;8(11):981.
23. O'Connor P, Filippi M, Arnason B, et al. for the BEYOND Study Group. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study [Errata]. Lancet Neurology 2012;11(1):27.
24. Pleimes D, Pohl C, Beckmann K, Stolz C. BEYOND Study -Data for Cochrane Analyses Protocol No. 306440. Bayer HealthCare Pharmaceuticals Affairs Specialized Therapeutics 2013.
25. Barbato LM, Schofield L, McCague K, Pestreich L, Tobias K, Malhotra M, et al. Randomized, open-label study to evaluate patient-reported outcomes (PRO) with fingolimod after changing from prior disease-modifying therapy (DMT) for relapsing multiple sclerosis. Proceedings of the 136th Annual Meeting Sunday, T1735. S73, September 25. 2011.
26. Beer K, Müller M, Hew-Winzeler AM, Bont A, Maire P, You X, et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. Bacteriologia, Virusologia, Parazitologia, Epidemiologia 2011;11(144):2-7.
27. Carra A, Onaha P, Luetic G, Burgos M, Crespo E, Deri N, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. European Journal Neurology 2008;15(4):386-93.
28. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010;70(12):1545-77.
29. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11.
30. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, FORTE Study Group. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology 2011;69(1):75-82.
31. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. European of Journal Clinical Pharmacology 2011;68(4):441-8.
32. Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis 2005;11(4):420-4.
33. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Multiple Sclerosis 2001;7(6):349-53.
34. Khan O, Bao F, Shah M, Caon C, Alexandros T, Selis A, et al. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study. Journal of the Neurological Sciences 2012;312:7-12.
35. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Annals Neurology 2013;73(6):705-13.
36. Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Archives of Neurology 2010;67(9):1055-61.
37. NCT01058005. Phase IIIa multicenter, randomized, open-label, parallel-group, active-controlled study to evaluate the benefits of switching therapy (glatiramer acetate or interferon beta-1a) to natalizumab in subjects with relapsing remitting multiple sclerosis. Study evaluating rebif, copaxone, and tysabri for active multiple sclerosis (SURPASS). http://clinicaltrials.gov/show/NCT01058005 (accessed 17 December 2013).
38. Ouallet JC. Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies [Traitements de fond de la sclérose en plaques: enseignements des études randomisées comparatives directes]. Reveu Neurologique 2010;166(1):21-31.
39. Qizilbash N, Mendez I, Sanchez-de la Rosa R. Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome. Multiple Sclerosis Clinical Therapy 2012;34:159-76.
40. Salama HH, Abu-Hashim EM, El Bakry MA, Zhang J, El Mongui A. Twelve-month comparative study of the impacts of IFNb-1a (Avonex), IFNb-1b (Betaseron) and glatiramer acetate (Copaxone) on the clinical, MRI and immunological responses in relapsing-remitting multiple sclerosis. Neurosciences (Official Journal of the Pan Arab Union of Neurological Sciences) 2003;8:93-4.
41. NCT00176592. Phase IV, rater-blinded, randomized study, comparing 250 mg of betaseron with 20 mg of copaxone in patients with the relapsing-remitting(RR) or CIS forms of ms using 3 tesla (3T) magnetic resonance imaging (MRI) with triple-dose gadolinium. ClinicalTrials.gov/show/NCT00176592 (accessed 25 October 2013).
42. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71(2):129-35. [MEDLINE: 18606967]
43. Cadavid D, Cheriyan J, Skurnick J, Lincoln JA, Wolansky LJ, Cook SD. New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. Journal Neurology Neurosurgery and Psychiatry 2009;80:1337-43.
44. Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, et al. Clinical consequences of MRI activity in treated multiple sclerosis. Multiple Sclerosis Journal 2011;17(9):1113-21.
45. Chard DT, Dalton CM, Swanton J, Fisniku LK, Miszkiel KA, Thompson AJ, et al. MRI only conversion to multiple sclerosis following a clinically isolated syndrome. Journal of Neurology Neurosurgery and Psychiatry 2011; Vol. 82, issue 2:176-9.
46. Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Archives of Neurology 2012;69:82-8.
47. Comi G, Filippi M, Wolinsky JS, European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging -measured disease activity and burden in patients with relapsing multiple sclerosis. Annals of Neurology 2001;49:290-7.
48. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17.
49. Coyle PK, Cornelisse P, Lehr L, Stubinski B. Time course of injection-site reactions to subcutaneous interferon beta-1a or glatiramer acetate in the REGARD Study. Proceedings of 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers, June 2-5, San Antonio, Texas, USA. 2010.
50. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [MEDLINE: 3802833]
51. Dhib-Jalbut S, Marks S. Interferon beta mechanism of action in multiple sclerosis. Neurology 2010;74(1 Suppl):17-24.
52. U.S. Food, Drug Administration. BETASERON Product Approval Information -Application No 103471-July 1993. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000_APPROV.pdf (accessed January 2011).
53. U.S. Food, Drug Administration. AVONEX Product Approval Information -Application N. 103628 -May 1996. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1996/ifnbbio051796l.pdf (accessed January 2011).
54. U.S. Food, Drug Administration. Copaxone Product Approval Information -NDA 020622/S-015 -March 2001. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020622_S015_COPAXONE_INJECTION_AP.pdf (accessed January 2011).
55. FDA. REBIF Product Approval Information -Application No 103780 -March 2002. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094508.pdf (accessed January 2011).
56. FDA. EXTAVIA Product Approval Information -Application No.125290 -August 2009. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/125290s0000ltr.pdf (accessed January 2011).
57. U.S. Food, Drug Administration. Safety -What is a Serious Adverse Event?. http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm (accessed November 2013).
58. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, et al. Interferon -1b and glatiramer acetate effects on permanent black hole evolution. Neurology 2011;76:1222-8.
59. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD008933]
60. Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, et al. Gray matter atrophy is related to long-term disability in multiple sclerosis. Annals of Neurology 2008;64(3):247-54.
61. Goodin DS. Disease-modifying therapy in multiple sclerosis. Update and clinical implications. Neurology 2008;71 Suppl 3:8-13.
62. Goodin D. Comparative studies of glatiramer acetate and interferon beta. International Multiple Sclerosis Journal 2008;15(2):39-41.
63. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, et al. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Multiple Sclerosis 2012;18:181-95.
64. GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal 2004;328:1490-4.
65. Brozek J, Oxman A, Schunemann H. GRADEpro. 3.2 for Windows. GRADE Working Group, 2008.
66. Hadjigeorgiou G, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, et al. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Journal of Clinical Pharmacy and Therapeutics 2013;38:433-9.
67. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
68. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
69. Hillert J. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No. Multiple Sclerosis Journal 2012;19(1):26-8.
70. Hutchinson M. In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary. Multiple Sclerosis Journal 2012;19(1):29-30.
71. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
72. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of Neurology 1996;39(3):285-94.
73. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76.
74. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33(11):1444-52. [MEDLINE: 84040263]
75. La Mantia, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD004678.pub2]
76. Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, et al. Efficacy and safety of interferon beta-1b sc in older RRMS patients-a posthoc analysis of the BEYOND study. Journal of Neurology 2013;260(7):1838-45.
77. Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, et al. The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: design and baseline characteristics. Multiple Sclerosis and Related Disorders 2012;1:81-6.
78. Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, Nelson F, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis -clinical outcomes. Proceedings of the 64th American Academy of Neurology Annual Meeting, PL02.00, Neurology Volume 78, April 24. 2012.
79. Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. EDSS changes in CombiRx: blinded, 7-year extension results for progression and improvement. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
80. Lublin F, Cofield S, Cutter G, Salter A, Wang J, Conwit R, et al. Relapse activity in the CombiRx trial: blinded, 7-year extension results. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
81. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology 2001;50(1):121-7. [MEDLINE: 11456302]
82. ® efficacy yielding outcomes of a new dose study. Neurology 2008;71:153.
83. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2009;8:981.
84. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2011; Vol. 10:115.
85. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Gooding D, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Errata. Lancet Neurology 2012;11:27.
86. Oleen-Burkey M, Cyhaniuk A, Swallow E. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. Journal of Medical Economics 2013;16(3):397-406.
87. Oliver BJ, Kohli E, Kasper LH. Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. Journal of the Neurological Sciences 2010 Dec 15 [Epub ahead of print].
88. Parkenov V, Schluep M, Du Pasquier R. Assessing risk of multiple sclerosis therapies. Journal of Neurosurgical Sciences 2013;332(1-2):59-65.
89. Pleimes D, Pohl C, Beckmann K, Stolz C. BEYOND Study -Data for Cochrane Analyses Protocol No. 306440. Bayer HealthCare Pharmaceuticals Affairs Specialized Therapeutics 2013.
90. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revision to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-6. [MEDLINE: 16283615]
91. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011;69(2):292-302.
92. Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 2013;84(10):1082-91.
93. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis:guidelines for research protocols. Annals of Neurology 1983;13(3):227-31. [MEDLINE: 83202737]
94. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
95. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74 Suppl 1:25-30.
96. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
97. Rice GPA, Incorvaia B, Munari LM, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002002]
98. Richards R, Sampson F, Beard S, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technology Assessment 2002;6(18):1-73. [MEDLINE: 12022938]
99. Rotstein DL, Mamdani M, O'Connor PW. Increasing use of disease modifying drugs for MS in Canada. Canadian Journal of the Neurological Sciences 2010;37(3):383-8. [MEDLINE: 20481274]
100. Rudick RA, Fisher E. Do interferon beta-1b and glatiramer acetate grow brain?. Lancet Neurology 2009;8(12):1085-6.
101. Rudick RA, Lee LC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight year follow-up. Archives of Neurology 2010 12 Jul [Epub ahead of print].
102. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
103. Sørensen S. REGARD: what can we learn from randomised, open-label, head-to-head studies?. The Lancet 2008; Vol. 7:864-6.
104. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
105. Vickrey BG, Hays RD, Harooni R, Harooni R, Ellison GW. A health-related quality of life measure for multiple sclerosis. Quality of Life Research 1995;4(3):187-206.
106. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
107. Weinstok-Guttman B, Rmanathan M, Zwadinov R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opinion on Biological Therapy 2008;8(9):1435-47. [MEDLINE: 18694361]
108. Wolinsky J, Narayana P, Nelson F, Datta S, Cofield S, Cutter G, et al. The CombiRx trial: a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in participants with relapsing remitting multiple sclerosis -MRI outcomes. Proceedings of the 64th American Academy of Neurology Annual Meeting, abstract S11.002, Neurology Vol 78 April 24. 2012.
109. Wolinsky J, Salter A, Narayana P, Datta S, Nelson F, Cofield S, et al. MRI outcomes in CombiRx: blinded, 7-year extension results. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
110. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Progress in Cardiovascular Diseases 1985;27(5):335-71.
111. Zagmutt F, Carroll C. A network meta-analysis assessing the rate of adverse events and drop outs of alternative treatments for relapsing forms of multiple sclerosis. Proceedings of the 65th American Academy of Neurology (AAN) Annual Meeting, Neurology vol 80. 2013.
112. Zivadinov R, Reder AT, Filippi M, Minagar A, Stüve O, Lassmann H, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71(2):136-44.